{
  "id": "5a6f7245b750ff4455000050",
  "type": "summary",
  "question": "What is the mode of action of teriparatide?",
  "ideal_answer": "Teripartide is is an effective anabolic (i.e., bone growing) agent used in the treatment of some forms of osteoporosis.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/26768289",
    "http://www.ncbi.nlm.nih.gov/pubmed/22403112",
    "http://www.ncbi.nlm.nih.gov/pubmed/16463613",
    "http://www.ncbi.nlm.nih.gov/pubmed/20205677",
    "http://www.ncbi.nlm.nih.gov/pubmed/15940379",
    "http://www.ncbi.nlm.nih.gov/pubmed/22370296",
    "http://www.ncbi.nlm.nih.gov/pubmed/20872215",
    "http://www.ncbi.nlm.nih.gov/pubmed/24625372",
    "http://www.ncbi.nlm.nih.gov/pubmed/17538470",
    "http://www.ncbi.nlm.nih.gov/pubmed/26104116",
    "http://www.ncbi.nlm.nih.gov/pubmed/19604460"
  ],
  "snippets": [
    {
      "text": "Teriparatide results in a rapid increase in bone-formation markers, followed by increases in bone-resorption markers, opening an \"anabolic window,\"a period of time when PTH is maximally anabolic. Teriparatide reverses the structural damage seen in osteoporosis and restores the structure of trabecular bone. It has a positive effect on cortical bone, and any early increases in cortical porosity appear to be offset by increases in cortical thickness and diameter.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20872215",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Teriparatide (recombinant human 1-34 parathyroid hormone) is used to treat women with menopausal osteoporosis and men at high risk for fractures.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20205677",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": ". A new class of drugs called anabolic agents, typified by teriparatide usher, has the potential to reconstitute destroyed bone and bring it to its pristine state. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17538470",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Teriparatide [PTH (1-34)] is a genetically engineered analog of human parathyroid hormone that acts as an anabolic drug by increasing activity in both osteoblasts and osteoclasts.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26768289",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Teriparatide (recombinant human parathyroid hormone ) is an anabolic agent approved for the treatment of patients at high risk for fracture.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19604460",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Teriparatide promotes bone formation, while bisphosphonates suppress bone resorption.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26104116",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS These results confirm the opposite mechanisms of action of teriparatide and alendronate on bone remodeling and confirm the bone formation effect of teriparatide.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15940379",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "teriparatide an anabolic drug for the treatment of patients with osteoporosis",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16463613",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Teriparatide, a treatment formula of parathyroid hormone (PTH) , is a powerful anabolic agent on bone, improving its mass, geometry and microarchitecture",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22370296",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The recombinant amino-terminal fragment of human parathyroid hormone (Teriparatide) is a bone anabolic agent which reduces fracture risk by increasing bone mass and improving bone microarchitecture.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22403112",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "https://meshb.nlm.nih.gov/record/ui?ui=D019379",
    "http://www.biosemantics.org/jochem#4250366",
    "http://www.biosemantics.org/jochem#4205694"
  ]
}